Literature DB >> 16647796

Benefits of combining aripiprazole to clozapine: three case reports.

Fábio Lopes Rocha1, Cláudia Hara.   

Abstract

OBJECTIVE: A substantial number of patients treated with clozapine shows insufficient response. The author presents the results of adding aripiprazole in patients resistant to clozapine.
METHOD: Three cases of individuals with psychotic symptoms despite clozapine use and with significant side effects that were treated via this combination are presented. Response was evaluated by clinical assessment.
RESULTS: Good clinical results were obtained in all three patients, with improvement of psychotic symptoms and of some of the side effects of clozapine.
CONCLUSION: The findings from this case series suggest that adjunctive therapy with aripiprazole can be of benefit for treating clozapine resistant schizophrenic patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16647796     DOI: 10.1016/j.pnpbp.2006.03.024

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  10 in total

1.  Safety and tolerability of antipsychotic polypharmacy.

Authors:  Juan A Gallego; Jimmi Nielsen; Marc De Hert; John M Kane; Christoph U Correll
Journal:  Expert Opin Drug Saf       Date:  2012-05-08       Impact factor: 4.250

2.  Quality of life in patients with schizophrenia: the impact of socio-economic factors and adverse effects of atypical antipsychotics drugs.

Authors:  Aurigena Antunes de Araújo; Diego de Araújo Dantas; Gemma Galgani do Nascimento; Susana Barbosa Ribeiro; Katarina Melo Chaves; Vanessa de Lima Silva; Raimundo Fernandes de Araújo; Dyego Leandro Bezerra de Souza; Caroline Addison Carvalho Xavier de Medeiros
Journal:  Psychiatr Q       Date:  2014-09

3.  Augmentation of clozapine with aripiprazole in severe psychotic bipolar and schizoaffective disorders: a pilot study.

Authors:  Alessandra Benedetti; Antonello Di Paolo; Marianna Lastella; Francesco Casamassima; Chiara Candiracci; Antonella Litta; Laura Ciofi; Romano Danesi; Lorenzo Lattanzi; Mario Del Tacca; Giovanni Battista Cassano
Journal:  Clin Pract Epidemiol Ment Health       Date:  2010-06-04

4.  Role of aripiprazole in treatment-resistant schizophrenia.

Authors:  Nilufar Mossaheb; Rainer M Kaufmann
Journal:  Neuropsychiatr Dis Treat       Date:  2012-05-29       Impact factor: 2.570

5.  Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review.

Authors:  Frederike Schirmbeck; Mathias Zink
Journal:  Curr Neuropharmacol       Date:  2012-03       Impact factor: 7.363

6.  Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors.

Authors:  Frederike Schirmbeck; Mathias Zink
Journal:  Front Pharmacol       Date:  2013-08-09       Impact factor: 5.810

Review 7.  Comorbid Obsessive-Compulsive Symptoms in Schizophrenia: Insight into Pathomechanisms Facilitates Treatment.

Authors:  Mathias Zink
Journal:  Adv Med       Date:  2014-06-11

8.  Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin).

Authors:  Deanna L Kelly; Heidi J Wehring; Amber K Earl; Kelli M Sullivan; Faith B Dickerson; Stephanie Feldman; Robert P McMahon; Robert W Buchanan; Dale Warfel; William R Keller; Bernard A Fischer; Joo-Cheol Shim
Journal:  BMC Psychiatry       Date:  2013-08-22       Impact factor: 3.630

Review 9.  Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome.

Authors:  Sang Won Jeon; Yong-Ku Kim
Journal:  Int J Mol Sci       Date:  2017-10-18       Impact factor: 5.923

10.  Clozapine augmentation with cariprazine for negative symptoms: a case series and literature review.

Authors:  Ebenezer Oloyede; Ivana Clark; Shubhra Mace; Eromona Whiskey; David Taylor
Journal:  Ther Adv Psychopharmacol       Date:  2022-01-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.